This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cachefo, A. Articles by Beylot, M. Search for Related Content PubMed PubMed Citation Articles by Cachefo, A. Articles by Beylot, M.

Hepatic Lipogenesis and Cholesterol Synthesis in Hyperthyroid Patients

INSERM, U-499, and Genalys, Université R. T. H. Laennec, Laboratoire de Biochimie, Hôpital E. Herriot, Centre de Recherche en Nutrition Humaine, Hôpital E. Herriot, 69008 Lyon, France

Address all correspondence and requests for reprints to: M. Beylot, M.D., Ph.D., INSERM, U-499, Faculté R. T. H. Laennec, Rue Guillaume Paradin, 69008 Lyon, France. E-mail: beylot{at}laennec.univ-lyon1.fr

Abstract

To determine the effect of hyperthyroidism on hepatic lipogenesis and cholesterol synthesis we measured these metabolic pathways (deuterated water method) in euthyroid and hyperthyroid subjects investigated in the postabsorptive state. Hyperthyroid patients had increased concentrations of glucose (P < 0.05), insulin (P < 0.05), nonesterified fatty acids (P < 0.01), and triglycerides (P < 0.05) and decreased levels of plasma cholesterol (P < 0.01). The contribution of hepatic lipogenesis to plasma triglycerides was largely increased in hyperthyroid subjects (23.0 ± 1.8% vs. 7.5 ± 0.2%; P < 0.001), whereas the fractional synthetic rate of cholesterol was moderately higher (5.0 ± 0.8% vs. 3.3 ± 0.2%; P < 0.05). mRNA levels of ß-hydroxy-ß-methyl glutaryl-coenzyme A reductase, measured in circulating mononuclear cells, were increased (P < 0.05), whereas those of low density lipoprotein (LDL) receptor and LDL receptor-related protein were unchanged. Sterol responsive element binding protein-1c mRNAs were undetectable in mononuclear cells from both groups of subjects. The large stimulation of hepatic lipogenesis in hyperthyroid patients is probably explained by both a direct action of thyroid hormones and the increase in insulin. It could contribute to their moderate rise in triglycerides levels. The decreased plasma cholesterol level is observed despite an enhanced synthetic rate and is thus related to an increased clearance rate. The lack of increased expression of LDL receptor and LDL receptor-related protein suggests that other receptors are implicated.

This article has been cited by other articles:

				M. D. Erion, E. E. Cable, B. R. Ito, H. Jiang, J. M. Fujitaki, P. D. Finn, B.-H. Zhang, J. Hou, S. H. Boyer, P. D. van Poelje, et al. From the Cover: Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index PNAS, September 25, 2007; 104(39): 15490 - 15495. [Abstract] [Full Text] [PDF]

				K. Hashimoto, M. Yamada, S. Matsumoto, T. Monden, T. Satoh, and M. Mori Mouse Sterol Response Element Binding Protein-1c Gene Expression Is Negatively Regulated by Thyroid Hormone Endocrinology, September 1, 2006; 147(9): 4292 - 4302. [Abstract] [Full Text] [PDF]

				K. Kawai, S. Sasaki, H. Morita, T. Ito, S. Suzuki, H. Misawa, and H. Nakamura Unliganded Thyroid Hormone Receptor-{beta}1 Represses Liver X Receptor {alpha}/Oxysterol-Dependent Transactivation Endocrinology, December 1, 2004; 145(12): 5515 - 5524. [Abstract] [Full Text] [PDF]

				A. Cachefo, P. Boucher, E. Dusserre, P. Bouletreau, M. Beylot, and C. Chambrier Stimulation of cholesterol synthesis and hepatic lipogenesis in patients with severe malabsorption J. Lipid Res., July 1, 2003; 44(7): 1349 - 1354. [Abstract] [Full Text] [PDF]

				F. Diraison, V. Yankah, D. Letexier, E. Dusserre, P. Jones, and M. Beylot Differences in the regulation of adipose tissue and liver lipogenesis by carbohydrates in humans J. Lipid Res., April 1, 2003; 44(4): 846 - 853. [Abstract] [Full Text] [PDF]

				F. Forcheron, A. Cachefo, S. Thevenon, C. Pinteur, and M. Beylot Mechanisms of the Triglyceride- and Cholesterol-Lowering Effect of Fenofibrate in Hyperlipidemic Type 2 Diabetic Patients Diabetes, December 1, 2002; 51(12): 3486 - 3491. [Abstract] [Full Text] [PDF]